AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 11, Pages 1727
Publisher
MDPI AG
Online
2019-11-05
DOI
10.3390/cancers11111727
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- (2019) Hirokazu Taniguchi et al. Nature Communications
- Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
- (2019) Yoko Tsukita et al. Molecular Cancer
- Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5- and hypoxia- dependent up-regulation of AXL
- (2019) Pierre-Yves Dumas et al. HAEMATOLOGICA
- Gilteritinib: First Global Approval
- (2019) Sohita Dhillon DRUGS
- Cross-talk between receptor tyrosine kinases AXL and ERBB3 regulates invadopodia formation in melanoma cells
- (2019) Or-Yam Revach et al. CANCER RESEARCH
- Immuno-Oncological Efficacy of RXDX-106, a Novel Small Molecule Inhibitor of the TAM (TYRO3, AXL, MER) Family of Kinases
- (2019) Yumi Yokoyama et al. CANCER RESEARCH
- A Niche-Dependent Myeloid Transcriptome Signature Defines Dormant Myeloma Cells
- (2019) Weng Hua Khoo et al. BLOOD
- Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance
- (2019) Gabriele D’Errico et al. ONCOGENE
- A novel human anti‐ AXL monoclonal antibody attenuates tumor cell migration
- (2019) Duan Yanting et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma
- (2019) Seon Min Woo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Axl and MerTK receptor tyrosine kinases maintain human macrophage efferocytic capacity in the presence of viral triggers
- (2018) Aleksander M Grabiec et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Axl inhibitors as novel cancer therapeutic agents
- (2018) Yingying Shen et al. LIFE SCIENCES
- ZNF224 is a transcriptional repressor of AXL in chronic myeloid leukemia cells
- (2018) Gaetano Sodaro et al. BIOCHIMIE
- HGF-induced formation of the MET–AXL–ELMO2–DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion
- (2018) Wenjing Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer
- (2018) Haley D. Axelrod et al. MOLECULAR CANCER RESEARCH
- Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer
- (2018) Jeanne M. Quinn et al. MOLECULAR CANCER THERAPEUTICS
- Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy
- (2018) Sutapa Sinha et al. Oncotarget
- Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
- (2017) C S Chim et al. LEUKEMIA
- Growth Arrest-Specific 6 Enhances the Suppressive Function of CD4+CD25+Regulatory T Cells Mainly through Axl Receptor
- (2017) Guang-ju Zhao et al. MEDIATORS OF INFLAMMATION
- Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models
- (2017) Zhiqiang Guo et al. Oncotarget
- Axl acts as a tumor suppressor by regulating LIGHT expression in T lymphoma
- (2017) Eun-Hee Lee et al. Oncotarget
- Multiple myeloma
- (2017) Shaji K. Kumar et al. Nature Reviews Disease Primers
- Autophagy induced by AXL receptor tyrosine kinase alleviates acute liver injury via inhibition of NLRP3 inflammasome activation in mice
- (2016) Jihye Han et al. Autophagy
- Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma
- (2016) N. Lendvai et al. BLOOD
- Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo
- (2016) E. M. Kosciuczuk et al. BLOOD
- MGUS to myeloma: a mysterious gammopathy of underexplored significance
- (2016) M. V. Dhodapkar BLOOD
- Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD)
- (2016) Jeng-Wei Lu et al. CANCER LETTERS
- Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia
- (2016) Isabel Ben-Batalla et al. CLINICAL CANCER RESEARCH
- Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin
- (2016) Yanli Jin et al. CLINICAL CANCER RESEARCH
- Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies
- (2016) Mihalis S. Kariolis et al. JOURNAL OF CLINICAL INVESTIGATION
- Axl signaling induces development of natural killer cells in vitro and in vivo
- (2016) Eun-Mi Kim et al. PROTOPLASMA
- Reprogramming the immunological microenvironment through radiation and targeting Axl
- (2016) Todd A. Aguilera et al. Nature Communications
- Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling
- (2016) Cun Wang et al. Theranostics
- Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow
- (2016) Kenji Yumoto et al. Scientific Reports
- AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
- (2015) Moshe Elkabets et al. CANCER CELL
- Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
- (2015) S. Sinha et al. CLINICAL CANCER RESEARCH
- CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia
- (2015) Romain Gioia et al. JOURNAL OF PATHOLOGY
- Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells
- (2015) S Sinha et al. LEUKEMIA
- Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia
- (2015) Viralkumar Patel et al. LEUKEMIA & LYMPHOMA
- The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung
- (2015) T Fujimori et al. Mucosal Immunology
- Polarization of tumor-associated macrophages and Gas6/Axl signaling in oral squamous cell carcinoma
- (2015) Kuo-Chou Chiu et al. ORAL ONCOLOGY
- Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells
- (2015) Mikaella Vouri et al. Oncotarget
- AXL is an oncotarget in human colorectal cancer
- (2015) Erika Martinelli et al. Oncotarget
- Axl as a mediator of cellular growth and survival
- (2015) Haley Axelrod et al. Oncotarget
- GAS6/AXL Axis Regulates Prostate Cancer Invasion, Proliferation, and Survival in the Bone Marrow Niche
- (2015) Yusuke Shiozawa et al. NEOPLASIA
- AXL Mediates Resistance to Cetuximab Therapy
- (2014) T. M. Brand et al. CANCER RESEARCH
- Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
- (2014) J S Waizenegger et al. LEUKEMIA
- An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis
- (2014) Mihalis S Kariolis et al. Nature Chemical Biology
- Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients
- (2013) Ju Han et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
- (2013) I. Ben-Batalla et al. BLOOD
- Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target
- (2013) I.-K. Park et al. BLOOD
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients
- (2013) J Boysen et al. LEUKEMIA
- GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
- (2013) S P Whitman et al. LEUKEMIA
- First Axl inhibitor enters clinical trials
- (2013) Cormac Sheridan NATURE BIOTECHNOLOGY
- LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
- (2012) S. Betty Yan et al. INVESTIGATIONAL NEW DRUGS
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target
- (2012) J D Paccez et al. ONCOGENE
- The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy
- (2010) A. K. Ghosh et al. BLOOD
- R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
- (2010) S. J. Holland et al. CANCER RESEARCH
- Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization
- (2010) J. M. E. M. COSEMANS et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- TAM receptors and the regulation of erythropoiesis in mice
- (2009) H. Tang et al. HAEMATOLOGICA
- Survival and Migration of Human Dendritic Cells Are Regulated by an IFN- -Inducible Axl/Gas6 Pathway
- (2009) S. Scutera et al. JOURNAL OF IMMUNOLOGY
- The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development
- (2008) I.-K. Park et al. BLOOD
- Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia
- (2008) Chih-Chen Hong et al. CANCER LETTERS
- Axl and Tyro3 Modulate Female Reproduction by Influencing Gonadotropin-Releasing Hormone Neuron Survival and Migration
- (2008) Angela Pierce et al. MOLECULAR ENDOCRINOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started